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ABSTRACT 
Objective: The present study aimed to evaluate those 3 compounds among 122 Thai natural products by using a molecular docking approach to 
inhibit Main Protease (Mpro) of SARS-CoV-2 (PDB code: 6Y2F), Angiotensin Converting Enzyme (ACE)-2 (PDB code: 1R4L), and PAK-1 kinase (PDB 
code: 5DEW).  
Methods: The evaluation was performed on the docking scores calculated using AutoDock Vina as a docking engine and interaction profile analysis 
through 2-dimensional visualization using LigPlot+. The determination of the docking score was done by selecting the conformation of the ligand 
that has the lowest binding free energy (best pose).  
Result: The results of this study indicate that overall, Panduratin A has the best affinity in inhibiting the main protease of SARS-CoV-2, ACE-2, and 
PAK-1 compared to other compounds.  
Conclusion: The three thai medicinal plants compound has the potential to be developed as specific therapeutic agents against COVID-19.  
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INTRODUCTION 
In late December 2019, it was noticed that several people in Wuhan 
city of Hubei Province, China, were suffering from SARS-like 
pneumonia. Later, the human to human transmission of 2019-nCoV 
was confirmed. By October 1st, the viruses have been spread into 
213 countries with 33,842,281 confirmed cases and 1,010,634 
confirmed deaths [1]. It means that COVID-19 has efficient human-
to-human transmission leading to its widespread outbreaks in many 
countries around the world [2, 3]. 
Until now, there is no FDA-approved or specific treatment for 
COVID-19 infection. Clinical guidance of the World Health 
Organization (WHO) and Centers for Disease and Control Prevention 
(CDC) only include prompt supportive care like oxygen therapy, 
fluid management, empiric antimicrobials (in case of sepsis), and 
others [1, 4]. Investigational agents reported some potential therapy 
for COVID-19 such as remdesivir or chloroquinone and combined 
protease inhibitor lopinavir-ritonavir, which are previously used to 
treat against SARS and MERS-CoV but their efficacy is still unclear 
and needs further evaluation [5-7]. On the other hand, the vaccine 
candidates for COVID-19 are still in development and takes about 
12-18 mo to release it into the market. However, finding a cure and 
specific treatments is being a great help for the international 
community. In the current crisis, to achieve a fast and reliable drug, 
we decided to do a virtual screening procedure via molecular 
docking to find the potential molecule inhibitors to combat the 
COVID-19 outbreak.  
SARS-CoV-2 is known to belong to the Coronaviridae (CoV) family. 
This brings up the opportunity to discover COVID-19 potential drugs 
based on prior research regarding other types of coronaviruses. 
Previous research has shown that Coronavirus protease is one of the 
most promising protein therapeutic targets to treat viral infection 
[8]. The enzyme cleaves polyproteins translated from viral RNA into 
12 smaller proteins that participate in viral replication [9]. Thus, 
viral replication can be blocked by inhibiting the activity of this 
enzyme [10]. Furthermore, currently, researchers from around the 
world are lending their expertise to develop drugs targeting this 
protein. An experiment by Zhang et al. (2020) exhibited that a 
peptidomimetic α-ketoamide compound, namely 13b, is effective in 
inhibiting the replication of SARS-CoV-2 in human Calu3 lung cells. 
The structure of SARS-CoV-2 protease bound with 13b has been 
crystallized and available under the protein data bank (PDB) ID 
6Y2F. This can be used for further computational study for COVID-
19 drug discovery. 
Another study conducted by Yan et al. in 2020 confirmed that the 
new coronavirus (SARS-CoV-2) has the same cellular receptors as 
SARS coronavirus (SARS-CoV), namely angiotensin-converting 
enzyme 2 (ACE-2) [11]. The activity of this protein is known to be 
inhibited by a potent inhibitor, namely MLN-4760. MLN-4760 can 
alter the conformation of ACE-2 that may advantageous to prevent 
binding with SARS-CoV-2 [12]. The structure of ACE-2 bound with 
MLN-4760 is available under the PDB ID 1R4L. 
Another protein target that can be used to find the potential new 
compound to treat SARS-CoV-2 is PAK-1. PAK1 is the major 
“pathogenic” kinase whose abnormal activation is responsible for a 
wide variety of diseases such as cancers, inflammation, viral 
infection, malaria, immuno-suppression, aging, and so on [13]. In 
2005, Chloroquine (CQ) show to suppress SARS/coronavirus 
infection in cell culture with lC50 around 1uM [14], although the 
precise molecular mechanism underlying its anti-viral activity 
remains unknown recently. In 2016, a Korean team found that CQ 
up-regulates p21 (a CDK inhibitor) whose expression is suppressed 
by PAK1 [13]. More recently, a tumor-suppressing phosphate called 
PTEN, which inactivates PAK1, was shown to suppress the 
coronavirus-induced LLC2-dependent fibrosis [15]. Furthermore, 
expression of LLC2 depends on the coronavirus receptor (ACE2)-
induced CK2/RAS-PAK1-RAF-AP1 signaling pathway [16]. These 
observations altogether clearly indicate the PAK1-dependency of 
coronaviral pathogenesis and strongly suggest, if not proven 
clinically yet, that PAK1-blockers, in general, could be useful for the 
treatment of current pandemic COVID-19 infection.  
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On the other hand, the latest research conducted by Kanjanasirirat 
et al. in 2020 [17] found the 3 most potent compounds as anti-SARS-
CoV-2 agents among 122 Thai natural products using fluorescence-
based SARS-CoV-2 nucleoprotein detection in Vero E6 cells coupled 
with plaque reduction assay. These three compounds consist of 
andrographolide, 6-gingerol, and pandurotin A. The present study 
aimed to evaluate those 3 compounds by using a molecular docking 
approach to inhibit Main Protease (Mpro) of SARS-CoV-2 (PDB code: 
6Y2F), Angiotensin Converting Enzyme (ACE)-2 (PDB code: 1R4L), 
and PAK-1 kinase (PDB code: 5DEW). 
MATERIALS AND METHODS 
Hardware 
Docking simulation between test compounds and SARS-CoV-2 main 
protease and ACE-2 were performed within a laptop with specifications 
of an Intel® Core™ i7-8550U @1.80 GHz processor, 8 GB of RAM, the 
Windows 10 Home Single Language 64-bit operating system, and an 
Intel® UHD Graphics 620 graphics processing unit. Meanwhile, docking 
simulation between test compounds and PAK-1 was done in a laptop 
with specifications of a processor (CPU) Intel® Core™ i7–7500U @ 2.70 
GHz, graphics processing unit (GPU) Nvidia® GeForce 940 MX and 8 GB 
RAM with Windows 10 Home Single Language 64-bit was used. 
Software 
The software used in this research are MarvinSketch (ChemAxon), 
AutoDockTools 1.5.6 (The Scripps Research Institute, Amerika), 
AutoDock Vina (The Scripps Research Institute, Amerika), 
Notepad++(GNU General Public License), Ligplot+(European 
Bioinformatics Institute, United Kingdom), VMD (University of Illinois, 
Urbana Champaign), and PyMOL 3D Quad Buffer (Schrödinger, inc.) 
Preparation of receptors 
The crystal structures of SARS-CoV-2 Main Protease (Protein Data 
Bank [PDB] Code: 6Y2F) were downloaded from the Protein Data 
Bank (RCSB PDB, http://www. rcsb. org). In this structure, SARS-
CoV-2 Main Protease is co-crystalized with inhibitor 13b. The second 
receptors, crystal structures of ACE-2 (Protein Data Bank [PDB] 
Code: 1R4L) was downloaded from the Protein Data Bank (RCSB 
PDB, http://www.rcsb.org). In this structure, ACE-2 is co-crystalized 
with inhibitor MLN4760. The third receptor that are going to use in 
this study, crystal structures of PAK-1 (Protein Data Bank [PDB] 
Code: 5DEW) was downloaded from the Protein Data Bank (RCSB 
PDB, http://www.rcsb.org). In this structure, PAK1 is co-crystalized 
with the selective inhibitor G-5555. Each receptor file is then loaded 
to Visual Molecular Dynamics (VMD) (University of Illinois, Urbana 
Champaign) to separate the protein from its native ligand to 
facilitate the docking studies with molecule candidates. Next, the 
separated protein was submitted to AutoDock Tools 1.5.6 for pdbqt 
file preparation. The protein refinement involved the addition of 
polar hydrogen atoms and merging non-polar hydrogen. 
Preparation of ligands 
All inhibitor candidates from the Thailand medicinal plants 
compounds, here termed as the ligand, were constructed in 2-
dimensional view, energy minimized, and converted to the 3-
dimensional structure using Marvin Sketch program (ChemAxon, 
Budapest, Hungary) then finished by saving all as PDB (protein data 
bank) format file for docking simulations. The information about all 
inhibitor candidates such as chemical structure and formula were 
retrieved from the PubChem database (https://pubchem. 
ncbi.nlm.nih.gov/) and tabulated in table 1. 
 
Table 1: Details of the ligands 
No. Compound Chemical formula Structure 
1 Andrographolide C20H30O5 
 
2 6-Gingerol C17H26O4 
 
3 Panduratin A C26H30O4 
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Validation of molecular docking method 
AutoDock Vina is selected to be the docking program used in this 
study. As the program requires a specific “search space” in the 
coordinate system of the receptor, it is required to do the validation 
procedure to find out the size and the coordinate of the grid box that 
will be used for molecular docking of test compounds. The native 
ligand bound to the selected receptor (SARS-CoV-2 Main Protease with 
inhibitor 13b, ACE-2 with inhibitor MLN-4760, and PAK-1 with 
inhibitor G-5555), was extracted and redocked in the binding pocket. 
Thereafter, it was found that the best grid structure and coordinates 
are tabulated in table 2. The genetic algorithm parameters were set to 
default which population size is 150, the maximum number of the 
evaluation set to medium, the maximum number of generations is 
27,000 and of top individuals that automatically survive is 1, and the 
rate of gene mutation and crossover were 0.02 and 0.8 respectively. 
The rest of the docking parameters were set to the default setting of 
the program. Here to verify the accuracy, ligand out from redocking 
was evaluated in terms of the root mean square deviation (RMSD) 
between the docked pose and the experimentally determined pose. 
The prediction was considered successful as the RMSD value obtained 
is less than 2.0 Å [18].  
Docking simulation 
Molecular docking simulation was carried out with AutoDock Vina 
(The Scripps Research Institute, La Jolla, CA, USA). As a newly 
developed program, AutoDock Vina significantly improves the 
accuracy of the binding mode predictions and achieves 
approximately two orders of magnitude speed-up compared to 
AutoDock 4 [19]. The grid box dimension and coordinates are based 
on the parameter optimization for each receptor-native ligand pairs. 
The docking study was performed using the ligands listed in table 1 
against 3 receptors: SARS-CoV-2 Main Protease, ACE-2, and PAK-1.  
Analysis and visualization of docked pose 
After docking simulation, poses with the highest negative binding free 
energy (kcal/mol) were selected as the best pose for corresponding 
ligand binding in the case of AutoDock Vina. The best-predicted poses 
were visualized and analyzed by PyMol (Schrödinger, Inc., New York, 
NY, USA). While the schematic representation of ligand and interacted 
residues inside the binding site of the receptor was then generated by 
LigPlot+(European Bioinformatics Institute, United Kingdom) 
program for a two-dimensional view [20].  
RESULTS AND DISCUSSION 
Validation of molecular docking results 
The results of RMSD value from the redocking process fulfill the 
requirements to have a value of less than 2.0 Å and are tabulated in 
table 2. 
Molecular interaction of Thai medicinal compounds and SARS-
CoV-2 main protease 
Docking simulation was performed to generate two results, which 
are the docking score and the most stable ligand pose. The docking 
score is generated from an empirical calculation that considers 
hydrophobic interactions and hydrogen bonding [19]. The docking 
score represents binding affinity, and it is inversely proportional to 
the binding stability [21]. In the meantime, the most stable ligand 
pose further will give the information of which amino acid interacts 
with the ligand spontaneously. By comparing the amino acid 
interacting with the potent inhibitor and with the test compound, 
the potency of a test compound to have the ability to inhibit the 
protein with the same pathway as the potent inhibitor may be 
predicted. The docking score between SARS-CoV-2 main protease 
and test compounds are available in fig. 1. 
  
Table 2: Parameter optimization results 
No. Receptor and native ligand pairs Grid box area Coordinates RMSD 























Fig. 1: Docking score between SARS-CoV-2 main protease and test compounds 
 
Based on the docking simulation, 13b bound to the main protease 
with a docking score of − 8.2 kcal/mol, while andrographolide, 6-
gingerol and panduratin A generated a docking score with the value 
of −6.6, −5.8 and −6.4 kcal/mol respectively. Although none of the 
test compounds generated a docking score that is less than the 
docking score of native ligand, the docking score of each compound 
is all negative. This indicated that all test compounds can bind with 
the protein. Andrographolide has the lowest docking score overall. 
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The interaction profile between SARS-CoV-2 main protease and 
inhibitor 13b, andrographolide, 6-gingerol, and panduratin A several 
are attached in fig. 2. The molecular interaction between SARS-CoV-
2 main protease and inhibitor 13b was firstly analyzed. According to 
the result, Inhibitor 13b generated hydrogen bonds with five amino 
acids, those are His41, Gly143, Ser144, Cys145, and Glu166. His41 and Cys145 
are known as the catalytic sites of SARS-CoV-2 main protease [22]. 
The shortest interatomic distance between inhibitor 13b and His41 
and Cys145 are 3.03 and 3.27 Å respectively. Interaction with these 
amino acids is important to inhibit the activity of the enzyme. 
  
 
Fig. 2: Docking score between SARS-CoV-2 main protease and test compounds, (a) inhibitor 13b, (b) andrographolide, (c) 6-gingerol, (d) 
panduratin A. The purple lines denote the ligand structure, whereas the brown lines denote the structure of amino acid residues. The 
molecular interactions are reflected as dashed lines and arcs. The green dashed lines between atoms represent hydrogen bonds, and the 
numbers above these lines indicate the length of the bond. Meanwhile, the arcs with spokes radiating toward the ligand atoms represent 
hydrophobic interactions. The atoms involved in hydrophobic interactions are indicated by the presence of spokes radiating back [20] 
 
The interaction profile between SARS-CoV-2 main protease and each 
test compounds was then analyzed. Andrographolide formed a 
hydrogen bond with Cys145 and interacted hydrophobically with 
His41. The interatomic distance between the compound and Cys145 is 
3.01 Å. This indicated that andrographolide may bind stronger to 
Cys145 compared to inhibitor 13b. In the meantime, 6-gingerol also 
formed a hydrogen bond with Cys145 and interacted hydrophobically 
with His41. Same as andrographolide, 6-gingerol also bound stronger 
to Cys145 compared to inhibitor 13b, with an interatomic distance of 
3.09 Å. Lastly, for panduratin A, it is shown that this compound 
formed a hydrogen bond with His41 and interacted hydrophobically 
with Cys145. The interatomic distance of 3.05 Å between the 
compound and His41 indicated that this compound may bind 
stronger to His41 compared to inhibitor 13b. Meanwhile, the 
hydrophobic interaction with catalytic sites shows that the 
compound may still have the potency to inhibit the activity of the 
enzyme. However, the binding affinity may not as strong as 
hydrogen bonds.  
Furthermore, the binding similarity between the interaction profile 
of SARS-CoV-2 main protease and each test compounds compared to 
the interaction profile of SARS-CoV-2 main protease and inhibitor 
13b was calculated. It was done to become another consideration in 
analyzing the potency of the test compounds to become SARS-CoV-2 
main protease inhibitors. Andrographolide, 6-gingerol, and 
panduratin A bound to SARS-CoV-2 main protease with the 
similarities of 63%, 69%, and 50% respectively. Table 3 summarizes 
the interaction profile between SARS-CoV-2 main protease and each 
test compound. 
 
Table 3: Interaction profile between SARS-cov-2 main protease and test ligands 




Inhibitor 13b Thr25, Cys44, Met49, Leu141, Asn142, His163, 
His164, Met165, Leu167, Asp187, Gln189 
His41, Gly143, Ser144, Cys145, Glu166 16 100% 
Andrographolide His41, Met49, Phe140, Leu141, Met165, Gln189 Asn142, Ser144, Cys145, His163, Glu166 11 63% 
6-Gingerol His41, Phe140, Asn142, Met165, Asp187, Arg188 Leu141, Gly143, Ser144, Cys145, His163, 
His164, Glu166 
13 69% 
Panduratin A Thr25, Thr26, Met49, Leu141, Asn142, Gly143, 
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Molecular interaction of Thai medicinal compounds and ACE-2 
The docking score between ACE-2 and test compounds are available 
in fig. 3. Based on the docking simulation, inhibitor MLN-4760 
bound to ACE-2 with a docking score of −9.2 kcal/mol. Meanwhile, 
andrographolide, 6-gingerol, and panduratin A generated a docking 
score with a value of −8.5, −7.3, and −9.6 kcal/mol respectively. The 
negative value of the docking score generated by all test compounds 
indicated that all test compounds can bind with the protein. 
Panduratin A has the lowest docking score above all. The value is 
also lower compared to inhibitor MLN-4760. It may indicate that 
panduratin A can bind stronger than inhibitor MLN-4760. 
 
 
Fig. 3: Docking score between ACE-2 and test compounds 
 
The interaction profile between ACE-2 and inhibitor MLN-4760, 
andrographolide, 6-gingerol, and panduratin A several are available in 
fig. 4. Unlike SARS-CoV-2 main protease, the key residues to inhibit the 
activity of ACE-2 is relatively unknown. Therefore, the hydrogen bonds 
between ACE-2 and MLN-4760 informed in the crystallographer 
report was used as a basis for analysis. The amino acids are Arg273, 
His345, Pro346, Thr371, and His505 [12]. According to the result, 
andrographolide interacted hydrophobically with His345 and Pro346. 
There is no interaction with the rest of the expected key residues. 
Meanwhile, 6-gingerol formed hydrogen bonding with one expected 
key residue, which is His345. The interatomic distance is known to be 
3.03 Å and is greater than the bond that exists in inhibitor MLN-4760. 
In the meantime, panduratin A formed hydrogen bonds with Arg273 
and Thr371and interacted hydrophobically with His345. The interatomic 
distance between panduratin A and Arg273 and Thr371are 3.13 and 2.75 
Å respectively. The hydrogen bond between panduratin A and Arg273 is 
weaker compared to in MLN-4760. However, the hydrogen bond 
between panduratin A and Thr371 is known to be stronger compared to 
the interatomic distance between MLN-4760 and Thr371 attachedin the 
crystallographer report, which is 3.0 Å. 
Furthermore, the binding similarity between the interaction profile 
of ACE-2 and each test compound compared to the interaction 
profile of ACE-2 and inhibitor MLN-4760 was also calculated to 
become further consideration. Andrographolide, 6-gingerol, and 
panduratin A bound to ACE-2 with the similarities of 15%, 8%, and 
46% respectively. Table 4 summarizes the interaction profile 
between ACE-2 and each test compound. 
 
 
Fig. 4: Docking score between ACE-2 and test compounds, (a) inhibitor 13b, (b) andrographolide, (c) 6-gingerol, (d) panduratin A. The 
purple lines denote the ligand structure, whereas the brown lines denote the structure of amino acid residues. The molecular interactions 
are reflected as dashed lines and arcs. The green dashed lines between atoms represent hydrogen bonds, and the numbers above these 
lines indicate the length of the bond. Meanwhile, the arcs with spokes radiating toward the ligand atoms represent hydrophobic 
interactions. The atoms involved in hydrophobic interactions are indicated by the presence of spokes radiating back [20] 
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Table 4: Interaction profile between ACE-2 and test ligands 




Inhibitor MLN-4760 Thr347, Glu375, Thr371, Glu402, Phe504, Tyr510 Arg273, His345, Pro346, His374, His378, 
His505, Tyr515 
13 100% 
Andrographolide Leu144, Ala153, Asp269, Trp271, His345, Pro346, 
Lys363, Asp368 
Tyr127, Glu145, Asn149, Asn277, Asp367 13 15% 
6-Gingerol Ser128, Thr129, Leu143, Glu145, Asp269, Trp271, 
Phe274, Ala342, Cys344. 
Tyr127, Leu144, Asn149, His345 13 8% 
Panduratin A Asp269, Phe274, His345, Asp367, Asp368, Leu370, 
His374, Glu375, Tyr515 
Arg273, Thr371 11 46% 
 
Molecular interaction of Thai medicinal compounds and PAK-1  
The docking score between PAK-1 and test compounds are available in 
fig. 5. Based on the docking simulation, inhibitor G-5555 bound to 
PAK-1 with a docking score of −9.5 kcal/mol. Meanwhile, 
andrographolide, 6-gingerol, and panduratin A generated a docking 
score with a value of −7.5, −6.2, and −7.4 kcal/mol respectively. The 
negative value of the docking score generated by all test compounds 
indicated that all test compounds can bind with the protein. 
Panduratin A has the lowest docking score above all test compounds. 
  
 
Fig. 5: Docking score between PAK-1 and test compounds 
 
 
Fig. 6: Docking score between PAK-1 and test compounds, (a) inhibitor G-5555, (b) andrographolide, (c) 6-gingerol, (d) panduratin A. The 
purple lines denote the ligand structure, whereas the brown lines denote the structure of amino acid residues. The molecular interactions 
are reflected as dashed lines and arcs. The green dashed lines between atoms represent hydrogen bonds, and the numbers above these 
lines indicate the length of the bond. Meanwhile, the arcs with spokes radiating toward the ligand atoms represent hydrophobic 
interactions. The atoms involved in hydrophobic interactions are indicated by the presence of spokes radiating back [20] 
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The interaction profile between PAK-1 and inhibitor G-5555, 
andrographolide, 6-gingerol, and panduratin A several are available 
in fig. 6. Unlike SARS-CoV-2 main protease, the key residues to 
inhibit the activity of PAK-1 is relatively unknown. Therefore, the 
hydrogen bonds between PAK-1 and inhibitor G-5555 informed in 
the crystallographer report was used as a basis for analysis. 
According to the result, andrographolide interacted hydrophobically 
with Glu315 and Lys299. There is no interaction with the rest of the 
expected key residues. Meanwhile, 6-gingerol formed hydrophobic 
and hydrogen bonding with one expected key residue, which is 
Glu315. In the meantime, panduratin A formed hydrogen bonds with 
Thr406 and interacted hydrophobically with Glu345, Lys299, Leu396, 
Met344, Asp393, Glu315, and Thr406  
Furthermore, the binding similarity between the interaction profile 
of PAK-1 and each test compound compared to the interaction 
profile of PAK-1 and inhibitor G-5555 was also calculated to become 
further consideration. Andrographolide, 6-gingerol, and panduratin 
A bound to PAK-1 with the similarities of 14.3%, 7.1%, and 50% 
respectively. Table 5 summarizes the interaction profile between 
PAK-1 and each test compound. 
 
Table 5: Interaction profile between PAK-1 and test ligands 
Compound Hydrophobic interactions Hydrogen bonds Number of 
interaction 
Binding similarity 
Inhibitor G-5555 Ile316, Val342, Met319, Glu315, Lys299, Met344, Tyr346, 
Thr406, Ala297, Leu347, Glu345, Glys350, Asp393, Leu396 
Leu347, Asp393 14 100% 
Andrographolide Pro469, Met424, Lys308, Val425, Phe410, Leu311, Gly409, 
Pro307, Glu315, Met301, Ser281, Ile312, Lys299 
Met424, Lys308, Val425, 
Glu315, Lys299 
13 14.3% 
6-Gingerol Asp407, Ile312, Glu315, Gly409, Leu311, Phe410, Arg388, 
Val425b, Met424, Pro469, Lys308, Val425a 
Lys308, Met424, Val425b, 
Glu315 
12 7.1% 
Panduratin A Leu347, Ile276, Glu345, Lys299, Val284, Ala297, Leu396, 
Met344, Asp393, Glu315, Asn394, Val328, Thr406 
Thr406 13 50% 
 
This study provides preliminary information about the most potent 
inhibitor of the protein Main Protease Sars-CoV-2, ACE-2, and PAK-1 
among 3 Thailand medicinal plant compounds. The suggested 
compound, hence, can be used as a reference to generate a lead 
compound for SARS-CoV-2 drug discovery in the future study. These 
residues may be the key to discover a new drug in the future or to 
develop the existing ones through modification of chemical structures. 
Docking study is a very useful method to predict the interaction 
between a ligand and receptor, however, it still has limitations due to 
the simplification of the method. Therefore, refinement of the docking 
results can be done further by approaching molecular dynamic 
simulation to give a more accurate binding prediction. 
CONCLUSION 
Despite comparable binding affinity obtained by anti-SARS-CoV-2 
biomarkers in Thailand medicinal compounds propolis toward main 
protease SARS-CoV-2, ACE-2, and PAK-1, this research suggested 
that panduratin A is the most potent inhibitor for the 3 biomarkers. 
In the whole study, it can be concluded that panduratin A is a 
promising candidiasis alternative that can be used as a reference to 
generate a lead compound for anti-SARS-CoV-2 drug discovery.  
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